Core Scientific Enters Cooperation Agreement with Two Seas Capital, Announces Board Refreshment
Summary
Core Scientific, Inc. has entered into a cooperation agreement with Two Seas Capital LP, a significant shareholder, to implement board refreshment and governance enhancements, including the appointment of three new independent directors and the departure of the current Chairman.
Key Events
-
Cooperation Agreement Signed
Core Scientific entered into a cooperation agreement with Two Seas Capital LP, a significant shareholder, on February 18, 2026.
-
Board Refreshment Plan
The company committed to appointing three new independent directors: one by March 15, 2026, a second by September 15, 2026, and a third by the 2027 Annual Meeting.
-
Chairman to Depart
Jordan Levy, the current Chairman of the Board, will not stand for re-election at the 2026 Annual Meeting.
-
Shareholder Stability
Two Seas Capital LP agreed to customary standstill provisions for one year and voting commitments until the 2027 Annual Meeting, reducing potential activist pressure.
Analysis
This 8-K filing details a significant cooperation agreement between Core Scientific and Two Seas Capital LP, a major shareholder. The agreement outlines a substantial board refreshment plan, including the appointment of three new independent directors over the next year and a half. Notably, the current Chairman, Jordan Levy, will not stand for re-election at the upcoming 2026 Annual Meeting, and another director will depart by the 2027 Annual Meeting. These changes suggest a proactive effort to enhance corporate governance and address shareholder interests. The inclusion of standstill provisions and voting commitments from Two Seas provides a period of stability, reducing the likelihood of further activist pressure and allowing the company to focus on its strategic objectives with a refreshed board structure.
At the time of this filing, CORZ was trading at $17.29 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $6.20 to $23.63. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.